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Amiodarone and the 
American Way* 
ROGER A. WINKLE, MD, FACC 
Palo Alto, California 
Amiodarone therapy remains controversial with a diversity 
of opinion regarding its efficacy and toxicity, the usefulness 
of electrophysiologic studies for predicting long-term suc•
cess and the risks and benefits of permitting its general 
availability. The drug is unique among cardiovascular com•
pounds in its methods of entry onto the American scene; a 
number of important lessons are to be learned from the 
amiodarone saga. The traditional method of initial clinical 
evaluation of a new compound in this country occurs after 
a long research and development process by the pharma•
ceutical industry, the initiation of clinical trials after suc•
cessful use in another country (usually also after a long 
research and development process) or the fortuitous dis•
covery that a compound already in existence has beneficial 
cardiovascular actions. When a compound is ready for clin•
ical trials the pharmaceutical industry sponsors the inves•
tigational new drug (IND) application at the Food .and D~g 
Administration (FDA). Formal protocols are wntten With 
review of the overall scientific program by expert consul•
tants from academia and clinical practice. Clinical trials are 
financially supported by the pharmaceutical industry and the 
drugs are carefully evaluated in a spectrum of studies. These 
studies typically include pharmacokinetic evaluations, stud•
ies in normal volunteers, hemodynamic and electrophysi•
ologic evaluations, studies in patients with mild, ~ode~ate 
and severe disease and evaluation in life-threatemng Situ•
ations. Clinical monitors from industry prod investigators 
into collecting and recording data in a way that will provide 
meaningful information to support a new drug application 
at some future date. This system usually results in adequate 
accumulation of data regarding the pharmacology, efficacy, 
toxicity and clinical indications for a drug before its wide•
spread use. 
Early investigational studies on amiodarone. 
Amiodarone, on the other hand, has followed an entirely 
different course. Although at every step the intentions 
of investigators, industry and the government have been 
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laudable and seemingly in the best interest of patients, the 
net result has been chaos and controversy often arising be•
cause of a paucity of scientific information. After encour•
aging reports from other countries (1,2), amiodarone was 
initially smuggled into this country by many of America's 
foremost cardiologists in a valiant effort to benefit their pa•
tients. The process achieved legitimacy when a large num•
ber of individual IND applications were approved by the 
FDA and an importing service and a major pharmaceutical 
company began to provide the drug free of charge. The 
United States Congress even got into the act by exempting 
the drug from the usual import tariffs, which had previously 
been paid by individual investigators from their own funds. 
At the time of its initial use in this country amiodarone was 
heralded as a miracle drug with little toxicity. However, 
given the difficulty in obtaining the drug and the quasi•
legality of its early use, investigators reserved it for the 
sickest patients after all other standard and investigational 
therapies had failed. Because of the critically ill nature of 
many of the patients and the lack of standardization provided 
by a coordinating pharmaceutical company, data collection 
was erratic. 
Many early reports (3-5) about the efficacy, safety and 
role of electrophysiologic studies with amiodarone involved 
only a small number of patients with limited follow-up. 
Because many of the toxic side effects of amiodarone were 
unknown at the time, they may have gone unnoticed, having 
been attributed to the patient's underlying disease process 
rather than the drug itself. Early reports indicated that some 
patients did well on amiodarone even though ven~ricul~r 
tachycardia remained inducible during electrophYSlOloglc 
studies. This observation was attractive to many investi•
gators caring for critically ill patients who had shown no 
improvement after treatment with multiple other standard 
and investigational drugs during electrophysiologic studies. 
A depressed patient who had been in the hospital for weeks 
could be given amiodarone and told that he or she would 
do well with this drug regardless of the outcome of elec•
trophysiologic study. For many patients treatment with 
amiodarone provided an opportunity for hospital discharge 
that had not seemed possible before. Amiodarone was rap•
idly and widely heralded as being different from other anti•
arrhythmic drugs with regard to the value of intracardiac 
electrophysiologic studies for predicting long-term success 
and many centers even stopped doing electrophysiologic 
studies in patients receiving it (6). 
Electrophysiologic testing: role in the amiodarone ex•
periment. When one scientific experiment gives a different 
outcome from all others, one must examine the situation 
carefully to determine whether the theory behind all of the 
experiments or the individual discordant experiment itself 
is flawed. Several factors suggest that the flaw lies with the 
amiodarone experiment rather than with the theory that elec-
0735-1097/85/$3.30 
lACC Vol. 6, No.4 
October 1985:822-4 
trophysiologic studies can predict long-term drug success. 
1) The patients undergoing therapy with amiodarone are 
considerably different from those undergoing treatment with 
other antiarrhythmic drugs. Patients ultimately undergoing 
electrophysiologic testing with amiodarone have not re•
sponded to a number of other antiarrhythmic drugs during 
electrophysiologic testing and many drug responders have 
been withdrawn from testing before amiodarone is given. 
In fact, it may be that patients receiving amiodarone are a 
selected subgroup of patients in whom the ability of elec•
trophysiologic inducibility or noninducibility of arrhythmia 
to predict long-term drug success somehow differs from that 
in the total patient group undergoing electrophysiologic study. 
2) Typically, with drugs other than amiodarone, patients 
sent home on a regimen on which their arrhythmia remains 
inducible have a very high rate of early recurrence of ar•
rhythmia with a flattening of the recurrence rate curve later 
in time. With all drugs a significant minority of patients 
will do well even though ventricular tachycardia is still 
inducible. Because in patients receiving amiodarone, the 
performance of electrophysiologic study may be delayed by 
several weeks or longer to be certain that amiodarone has 
accumulated, many patients with persistent clinical ventric•
ular tachycardia may undergo electrophysiologic testing after 
very long periods or may not undergo electrophysiologic 
study at all, and are declared nonresponders on clinical 
grounds. Those patients remaining arrhythmia-free for sev•
eral weeks while awaiting repeat electrophysiologic study 
may be a selected population biased strongly in favor of 
those who will do well even though their arrhythmia remains 
inducible. This group has, in fact, survived several weeks 
of a clinical trial before undergoing electrophysiologic study 
and may represent the flatter portion of the ventricular tachy•
cardia recurrence curve. By analogy, if follow-up electro•
physiologic studies were performed on patients receiving 
quinidine only after they had been treated successfully with•
out a clinical recurrence of ventricular tachycardia for 2 to 
4 weeks, a very high proportion of patients treated with 
quinidine might appear to do well despite inducible 
arrhythmia. 
3) Because of amiodarone's pharmacokinetics, intermit•
tent noncompliance during long-term therapy may play a 
smaller role in arrhythmia recurrence than it does with other 
antiarrhythmic drugs. As many as 10 to 15% of long-term 
antiarrhythmic drug failures may be secondary to intermit•
tent noncompliance. Removal of this factor for amiodarone 
probably plays a role in permitting a higher proportion of 
patients receiving this drug to do well when compared with 
patients receiving other antiarrhythmic drugs with a shorter 
half-life and less total body accumulation. 
4) In some recurrences of ventricular tachycardia during 
amiodarone therapy, the rate may be slower and the ar•
rhythmia not readily appreciated by the patient. Although 
this may indicate a clinically successful outcome of therapy, 
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failure to detect asymptomatic episodes may bias the long•
term predictive value of electrophysiologic studies. 
5) Most studies establishing the role of ventricular tachy•
cardia inducibility for predicting the long-term efficacy of 
drug therapy have utilized careful life-table analysis of long•
term recurrence and statistical assessment of the role of 
inducibility (7). The majority of early studies reporting on 
amiodarone (3,4,8,9) failed to apply these standard tech•
niques. In fact, several more recent studies utilizing tech•
niques of discriminant analysis and life-table analysis have 
indicated that ventricular tachycardia inducibility during 
electrophysiologic study in patients receiving amiodarone 
may well be a powerful predictor of arrhythmia recurrence 
and long-term outcome (10,11). 
Electrophysiologic versus noninvasive monitoring 
studies to identify patients at high or low risk for ar•
rhythmia recurrence. Operating under the possibly false 
assumption that ventricular tachycardia inducibility during 
electrophysiologic study has no value, two studies in this 
issue of the J oumal (12,13) attempt to define other electro•
physiologic or electrocardiographic findings that will help 
to define long-term drug success. After examining these 
studies one is struck by the overall poor amiodarone success 
rate of amiodarone. In the study by Naccarelli et al. (12), 
14 (40%) of 35 patients had a clinical recurrence of ar•
rhythmia with a follow-up period of just over 1 year and in 
the study by Veltri et al. (13), almost 50% had a clinical 
recurrence by 1 '12 years. These high failure rates may reflect 
the finding that many patients receiving amiodarone (in fact, 
all of the patients in the study by Naccarelli et al.) remain 
with ventricular tachycardia inducible at electrophysiologic 
study. Both studies do provide important information to help 
identify patients at high and low risk for long-term arrhyth•
mia recurrence. These two studies, however, examine en•
tirely different patient popUlations. The patients in the study 
of Naccarelli et al. were selected for repeat electrophysio•
logic study with amiodarone alone only if they had non•
sustained ventricular tachycardia suppressed on noninvasive 
monitoring. Thus, their patients would seem similar to the 
"ventricular tachycardia absent" patient discussed by Veltri 
et al. Taking these studies at face value, one might suggest 
a clinical approach to patients treated with amiodarone. If 
nonsustained ventricular tachycardia persists during non•
invasive monitoring, amiodarone is unlikely to succeed. For 
those patients free of nonsustained ventricular tachycardia, 
an electrophysiologic study can be performed. If no ven•
tricular tachycardia is inducible, patients are likely to do 
well (10,11). If ventricular tachycardia remains inducible 
the criteria suggested by Naccarelli et al. can be applied to 
select those who would do well and should remain on drug 
therapy. The patients with persisting nonsustained ventric•
ular tachycardia on noninvasive testing or those predicted 
to do poorly by the criteria of Naccarelli et al. can be selected 
for automatic defibrillator implantation or other surgical 
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therapy. Before widespread application of this approach, 
however, prospective studies must be performed utilizing 
these retrospectively determined criteria to test their validity. 
One final point seems worth making. The data analysis 
carried out by Veltri et al. utilizing sensitivity, specificity 
and predictive accuracy is less valuable than it would seem 
at first glance. This type of data analysis is most suitably 
used to examine the value of a test with an immediate 
outcome such as the ability of the exercise treadmill test to 
predict the presence or absence of coronary artery disease 
at an angiographic study. It is not well suited to the as•
sessment of long-term antiarrhythmic drug outcome since 
there is no way to control for duration of follow-up. The 
percent predictive accuracy will be different depending on 
the duration of follow-up. The analysis would be improved 
if one compared the percent predictive accuracy at 1 and 2 
years of various tests or, better yet, limited presentation to 
the use of life-table techniques. 
The future of amiodarone. Regardless of our ability to 
predict long-term outcome, the ultimate value of amioda•
rone may be seriously limited by its significant toxicity. The 
lack of a coordinated central effort sponsored by the phar•
maceutical industry to tabulate the precise incidence of drug 
toxicity due to amiodarone has led to an ad hoc movement 
among a number of investigators to form the Amiodarone 
Toxicity Study Group. It is hoped that this data collection 
being coordinated through the Cardiology Division at the 
University of Utah will provide meaningful data concerning 
the long-term toxicity of amiodarone. 
The evolution of the amiodarone story in the United 
States indirectly lends a strong note of support for the much 
maligned drug evaluation and approval process in this coun•
try. Although we frequently have industry pointing fingers 
at the FDA, FDA pointing fingers at industry, investigators 
pointing fingers at both industry and the FDA and consumer 
advocates pointing fingers at everyone, nonetheless, the im•
perfect process that does exist generally provides a firm 
scientific basis on which rational decisions can be made 
regarding the efficacy, toxicity and clinical indications of a 
new drug. Failure to follow these traditional avenues has 
resulted in an unfortunate situation where investigators, in•
dustry and government feel compelled to do something, yet 
no one knows precisely what to do. Caught in the middle 
are the thousands of patients currently receiving amiodarone 
and at risk are the tens of thousands of patients who might, 
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in fact, be harmed by the wrong decision. Although it seems 
at this time almost too late to begin anew with amiodarone, 
the lesson learned is obvious and the same mistakes should 
not be repeated in the future. 
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